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Implementing evidence-based science to improve women’s
health globally☆Box 1
Implementation science: Evidence-based practices to improvewomen’s
health globally
• Highly active antiretroviral therapy for preventing mother-to-
child transmission of HIV [9,10]
• Active management of the third stage of labor [12]
• Bimanual compression [18]
• Tamponade/compression sutures (e.g. B-Lynch) [19–22]
• Safer cesarean (tranexamic acid) [40,41]
• Magnesium sulfate (Magpie Trial) [37–39]
• Manual vacuum aspiration [35,36]
• Misoprostol [23–34]
• Cervical cancer: visual inspection with acetic acid/see andTimothy R.B. Johnson, MD
Editor, IJGO
For over 25 years, the leaders of our specialty and of FIGO have
eloquently directed the world’s attention to the global plight of
women’s health. In his landmark article “Where is the M in MCH?”
[1], Allan Rosenfield highlighted the unacceptably high toll of mater-
nal mortality and gave fuel to the subsequent Safe Motherhood Initia-
tive. FIGO President Mahmoud Fathalla [2] spoke eloquently and
often of the importance of enhancing the role and privileges given
to women by society. Subsequent FIGO Presidents have all added
their voices in this call to action [3–6]. Increasingly, the inequity of
high maternal mortality—as well as such horrors as genocidal and
systematic rape, fistula, female genital mutilation, interpersonal vio-
lence, and the high burden of AIDS and HPV—is being recognized by
governments and international bodies.☆ Presented in part as the Donald F. Richardson Memorial Lecture, American College
of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting; May 2012; San
Diego, CA, USA.
0020-7292/$ – see front matter © 2013 International Federation of Gynecology and Obstetrics.
http://dx.doi.org/10.1016/j.ijgo.2013.05.003It is now clear that we have evidence-based interventions and
programs [7,8]—many of which have been reported and described
in the pages of the International Journal of Gynecology and Obstetrics
(IJGO)—that can substantially improve women’s health (Box 1). Since
1994 [9], we have known that modern perinatal antiretroviral therapy
(ART and subsequent HAART) can reduce the mother-to-child trans-
mission of HIV from 25% to less than 1% [10]. Despite scientific denial
by prominent leaders—including physician health ministers—that HIV
causes AIDS [11], important implementation programs with support
from such entities as PEPFAR and the Gates Foundation have demon-
strated reduction in perinatal transmission and have extended the
lives of women found to be HIV positive after voluntary counseling and
testing. The joint campaign by FIGO and the International Confederation
of Midwives to implement active management of the third stage of
labor worldwide is also a strongly evidence-based practice [12], and
the application of routine uterotonics, cord traction, anduterinemassage
is now becoming the standard of practice across the world [13–16].
Implementation science has been defined as programs and pro-
cesses that “promote the uptake of research findings into routine
healthcare in both clinical and policy contexts” [17].
Management of postpartumhemorrhage (PPH) using bimanual com-
pression [18] and such techniques as B-Lynch and other compressive/-
hemostatic sutures and Bakri balloons [19–22] has been shown to
impact the problem of PPH significantly. Misoprostol has now been
shown in a variety of studies to be an effective intervention for reducingtreat/HPV capture/HPV vaccine
• Breastfeeding (bleeding, neonatal, contraceptive benefits)
• Family planning (postpartum, postabortion care, long-acting
contraception, non-contraceptive benefits) [42]
Published by Elsevier Ireland Ltd. All rights reserved.
92 EditorialPPH in both primary and tertiary healthcare facilities, and with skilled-
birth-assisted and home deliveries [23–25]. Misoprostol and manual
vacuum aspiration (MVA), both individually and in combination,
can be major contributors to reducing complications associated with
incomplete abortion and improve access to care for women with
requirements for all types of postabortion care [26–36]. Now that the
science has demonstrated efficacy across multiple uses, many non-
governmental organizations and national/health entities are stepping
up to implement access to these life-saving interventions through ac-
quisition, supply chain distribution, and access/provision of services.
There has been substantial frustration with delays in the imple-
mentation of clear and evident scientific findings into practice. The
Magpie Trial demonstrated that magnesium sulfate (MgSO4) is effec-
tive in reducing the risks and complications of eclampsia and pre-
eclampsia [37], yet the drug is not even widely available in some of
the countries and even some of the sites in the low-income countries
where the Magpie Trial was carried out. One could propose that one
of the requirements for ethical approval of important randomized
clinical trials is a communication and implementation arm, especially
for trials that could have significant international impact on morbidi-
ty and mortality. MgSO4 has only recently been added to the WHO
list of essential drugs, but given the high toll of hypertensive compli-
cations of pregnancy it must now urgently become a priority focus
for health services worldwide [38,39]. There is strong evidence that
tranexamic acid (TXA) can reduce blood loss and hemorrhagic com-
plications of cesarean delivery [40,41], yet the drug is not available
in many countries, including the USA. We must be prepared for
widespread distribution and uptake of TXA if current ongoing trials
demonstrate efficacy in broadly reducing the risks of PPH.
We have long known that family planning prevents unwanted
pregnancy—thereby reducing maternal mortality—and permits birth
spacing, yet comprehensive, continuous, and coordinated services
are often lacking and/or confounded by the compartmentalization of
family-planning services separate from other services that women
need and want [11]. International guidelines are available to guide
best practices [42]. Uptake of breastfeeding to reduce postpartum
bleeding, improve infant survival, and provide the contraceptive ben-
efits of lactational amenorrhea would increase with strongly designed
and supported implementation programs.
Implementation science as defined above must include capacity
building, operational planning, behavioral psychology, logistics, oper-
ations research, and business marketing. Implementation engineering
will develop and introduce evidence-based devices that will improve
wellness and health. As obstetricians and gynecologists devoted to
the best care and services for our patients, we must heed the call to
action by our articulate and visionary leaders. We need to embrace
and champion programs that implement scientific discovery and
evidence-based practice, especially those most likely to have signifi-
cant impact on saving women’s lives [43–49].
It is clear that the implementation of evidence-based science pro-
grams has now developedmodels of infrastructure and human capac-
ity distribution that can optimize women’s health services. Programs
have been developed for the effective distribution of drugs to treat
HIV/AIDS and for drug-impregnated nets to control malaria. These ex-
emplars will be useful as we implement new therapies and programs
targeted at key areas of women’s health. Pre-pregnancy contraception
requires distribution of both knowledge and contraceptive methods.
These need to be available, accessible, affordable, and acceptable.
This will require an “operating system,” which means developing
informed and skilled human resources. It is not possible to immunize
women against PPH. It is unlikely there will ever be a drug to prevent
obstructed labor. A spectrum of skilled birth attendants with the ca-
pacity to identify and manage PPH, pre-eclampsia, and labor dystocia;
systems of referral and transportation; and access to essential drugs
(including misoprostol, oxytocin, MgSO4, and blood products) and
therapies (including the ability to remove a retained placenta andperformMVA and cesarean delivery) will be required to meet our im-
plementation goals.
IJGO will continue to publish scientific papers presenting inter-
ventions that can save women’s lives. The journal has been a major
source of scientific and medical therapy concerning PPH and the ob-
stetric and gynecologic applications for misoprostol (see references).
IJGO maintains a particular interest in articles addressing medical and
psychosocial issues that remain a major burden to women in low-
and middle-income countries. We also solicit submissions that care-
fully describe effective programs and methods for implementing
evidence-based best practices to allow all women everywhere to
live in health and safety and that help to achieve the goals and aspira-
tions of FIGO.References
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